10-K: Ludwig Enterprises Inc. Files 2023 Annual Report, Highlights mRNA Technology and Financial Challenges

Ludwig Enterprises Inc. released its 2023 annual report, detailing its focus on mRNA technology for disease detection and treatment, while also acknowledging significant financial losses and a going concern warning.

Summary

• Ludwig Enterprises Inc. is a genomic technology company focused on developing products using mRNA inflammatory markers to assess and treat inflammation-related diseases.
• The company's subsidiaries include mRNAforLife, Inc., Precision Genomics, Inc., and Exousia Ai, Inc., each focusing on different aspects of the business.
• The company is developing home test kits and genetic-centric supplements to personalize healthcare based on individual mRNA profiles.
• The company reported a net loss of $2,456,550 for the year ended December 31, 2023, and a working capital deficit of $1,461,565.
• The company has not yet generated revenue from operations and is dependent on raising additional capital to execute its business plan.
• The company's financial statements include a going concern warning, indicating substantial doubt about its ability to continue operations without additional funding.
• The company is pursuing research studies in areas such as bladder cancer, preeclampsia, and cardiovascular diseases.
• The company is developing a proprietary mRNA Inflammatory Index microarray technology to measure inflammatory biomarkers.
• The company plans to market its products through both B2B and B2C channels, including wellness centers, physicians, and online sales.
• The company has filed patents related to its mRNA technology and nutritional supplement program.

Sentiment

Score: 4

Explanation: The document highlights innovative technology and a clear strategy, but the significant financial losses, going concern warning, and dependence on external funding create a negative sentiment. The company's future is highly uncertain.

Positives

• The company is developing innovative mRNA-based technology for personalized medicine.
• The company has a proprietary mRNA Inflammatory Index microarray technology.
• The company is pursuing research studies in multiple disease areas.
• The company has filed patents related to its technology and supplement program.
• The company has a clear strategy for marketing and distribution of its products.

Negatives

• The company has not yet generated revenue from operations.
• The company reported a significant net loss of $2,456,550 for 2023.
• The company has a substantial working capital deficit of $1,461,565.
• The company's financial statements include a going concern warning.
• The company is dependent on raising additional capital to continue operations.
• The company's internal controls over financial reporting were deemed not effective.
• The company's stock is traded on the OTC Pink tier, which is considered volatile and risky.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital.
• The company may not be able to obtain product liability insurance for its test kits.
• The company's manufacturing and distribution are dependent on third parties.
• The company's products may not be classified as Laboratory Developed Tests (LDTs), which could force the company to cease sales.
• The company faces competition from other genetic testing companies.
• The company's stock is subject to penny stock rules, which may reduce trading activity.
• The company's internal controls over financial reporting were deemed not effective.
• The company's executive officers and directors have other business interests, which may create conflicts of interest.

Future Outlook

The company expects revenues from sales of its planned products to begin during the third quarter of 2024, assuming it can obtain needed funding of approximately $1,500,000. The company also anticipates that its operating expenses for 2024 will be higher than those incurred in 2023.

Management Comments

• Management believes the future of healthcare will focus on personalized medicine that is preventative, rather than reactive.
• Management believes that the healthcare system, as it is currently structured, can be improved.
• Management believes that the company's technology provides an opportunity to integrate genetic technology into the diagnosis and treatment continuum of a patient.
• Management aspires to provide more individualized care through nutritional supplementation, tailored to the genetic makeup of the individual.

Industry Context

The company operates in the growing field of personalized medicine and genomic technology, with a focus on mRNA-based diagnostics and therapeutics. The company's approach aligns with the trend towards preventative healthcare and the use of genetic information to tailor treatments. The company's focus on inflammation also aligns with the growing recognition of the role of inflammation in many chronic diseases.

Comparison to Industry Standards

• The company's focus on mRNA technology differentiates it from competitors that primarily focus on DNA-based testing, such as 23andMe Inc., Alpha Laboratories Ltd., and Centrillion Technology Holding Ltd.
• The company's approach to personalized medicine through mRNA indexing and supplementation is unique in the market.
• The company's use of machine learning AI to analyze mRNA data is in line with industry trends in bioinformatics and data analysis.
• The company's planned research studies in bladder cancer, preeclampsia, and cardiovascular diseases are aligned with areas of significant unmet medical need.
• The company's financial performance is significantly below industry standards for companies in the biotechnology sector, particularly in terms of revenue generation and profitability.
• The company's reliance on external funding is a common challenge for early-stage biotechnology companies, but the going concern warning is a significant concern.

Management Changes

Corporate Governance

Legal Proceedings

• The company has no pending legal or administrative proceedings.

Related Party Transactions

• The company repurchased 171,162,746 shares of its common stock from Worthington Financial Services, Inc. in exchange for a promissory note.
• The company entered into a consulting agreement with Homeopathic Partners, Inc., which was later terminated.
• The company's Chief Operating Officer, Thomas Terwilliger, owns Corporate World, Inc., which serves as the company's registered agent.
• The company entered into a Financial Advisory Services Agreement with EverAsia Financial Group, Inc., a financial consulting firm owned by Scott J. Silverman, who was appointed as the company's Chief Financial Officer.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial challenges and going concern warning.
• Employees may be impacted by the company's financial instability and potential need for restructuring.
• Customers may be impacted by potential delays in product development and commercialization.
• Suppliers and creditors face risk due to the company's financial instability and potential inability to meet its obligations.

Next Steps

• The company intends to submit its OTCQB application.
• The company plans to begin commercial sales of its NuGenea product in late 2023.
• The company intends to launch its testing kits as a Laboratory Developed Test (LDT).
• The company plans to conduct research studies in bladder cancer, preeclampsia, and cardiovascular diseases.
• The company intends to analyze approximately 3,000 mRNA samples from patients with various chronic inflammatory diseases.
• The company plans to develop specific antibodies that bind to key diagnostic genes and market them to biotech and pharma companies.
• The company intends to obtain product liability insurance for its test kits.
• The company intends to secure a warehouse facility for storing finished products.
• The company intends to file a registration statement with the SEC with respect to shares of common stock issuable to an investor.

Key Dates

Keywords

mRNA, genomics, inflammation, precision medicine, nutraceuticals, biomarkers, artificial intelligence, LDT, clinical studies, genetic testing